It is possible that a subset of ST2 tumors represents B-cell neoplasms derived from GCB cells that have undergone terminal B-cell differentiation, driven by the sustained expression of plasma cell differentiation-related genes such as PRDM1/Blimp1 [33], and reinforced by the activation of the NF-κB and JAK/STAT pathways, among other potential oncogenic events. This evidence concerns the gene SOAT1 and B-cell neoplasm.